Скачать или смотреть Dr. Levis on a Phase II Trial Examining Quizartinib in AML

Mark J. Levis, MD, PhD, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses the design and results of a phase II trial of quizartinib in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia.

Quizartinib is directed against FLT3, an enzyme which leads to a poor prognosis in patients with AML. The two cohorts in the study were an older cohort that failed the first line of therapy and a younger cohort that had failed two lines of therapy. Patients received the drug as a single dose daily and tolerated it well. Levis said that the dosage was higher than it needed to be to achieve the desired effect. The trial had a 46% composite complete remission rate.

For more resources, visti: http://targetedhc.com/